Giuseppe Lamberti

IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status”.

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.10.013

N/A

8.9DataRank · unranked

377 citations

Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong +28 more

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3608

N/A

0.811DataRank · unranked

222 citations

Magda Bahcall, Liam F. Spurr, Jianwei Che, Biagio Ricciuti, Giulia C. Leonardi +18 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.07.005

N/A

0.701DataRank · unranked

106 citations

Joao V. Alessi, Arielle Elkrief, Xinan Wang, Alessio Cortellini, Y Y Li +27 more

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1207

N/A

0.542DataRank · unranked

36 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Hira Rizvi, Arielle Elkrief +23 more

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature Communications(2023)10.1038/s41467-023-39874-8

N/A

0.515DataRank · unranked

30 citations

Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti +13 more

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-006994

N/A

0.416DataRank · unranked

15 citations

Joao V. Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

The Oncologist(2023)10.1093/oncolo/oyad197

N/A

0.385DataRank · unranked

12 citations

Biagio Ricciuti, Joao V. Alessi, Teng Fei, Hannah L. Kalvin, Jacklynn V. Egger +16 more

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2990

N/A

0.312DataRank · unranked

7 citations

Rohit Thummalapalli, Stephanie Alden, Biagio Ricciuti, Joao V. Alessi, Arielle Elkrief +18 more

Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study

medRxiv(2022)10.1101/2022.12.05.22283131

N/A

0DataRank · unranked

0 citations

Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers

Research Square(2022)10.21203/rs.3.rs-2273813/v1

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Xinan Wang, Giuseppe Lamberti, Arielle Elkrief, Federica Pecci +12 more

Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9107

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Jia Luo, Joao Victor Machado Alessi +13 more

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Drugs in Context(2022)10.7573/dic.2022-7-4

N/A

0DataRank · unranked

13 citations

Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci +6 more